Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX000189 in moderate to severe active SLE
NCT05967520Phase 2Recruiting
- Sponsor
- Jemincare
- Start
- Sep 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of JMKX000189 in systemic lupus erythematosus (SLE) (3 arms), sponsored by Jemincare. Primary endpoint: Change in Total Lymphocyte Count From Baseline at 12 weeks. Started Sep 2023; status: recruiting.
02
Drugs
JMKX000189
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05967520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967520.